Hospital
Tarzana Medical Center LLC
Tarzana Medical Center LLC was paid $15.24M by Medicaid between Jan 2018 and Dec 2024, across 241 billing codes. Its largest line is 0450, Emergency room services — 27% of everything it billed.
33Billing provider infoTARZANA MEDICAL CENTER LLC
TARZANA, CA 91356
TARZANA, CA 91356
33aNPI1821250762assigned 07/01/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.24M
24GClaims619,355
24DCodes billed241
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#144 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,589 | $1.79M | |
| 2019 | 84,578 | $2.43M | |
| 2020 | 61,521 | $1.07M | |
| 2021 | 76,126 | $1.57M | |
| 2022 | 93,932 | $2.38M | |
| 2023 | 106,942 | $2.87M | |
| 2024incomplete | 104,667 | $3.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 27% | 86,741 | 78,041 | $4.07M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.4% | 10,915 | 9,481 | $971K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5.4% | 7,900 | 7,717 | $816K |
| 80053 | Comprehensive metabolic panel | 4.4% | 30,334 | 27,835 | $674K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 5,422 | 5,233 | $611K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 3,168 | 2,957 | $484K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 4,162 | 4,079 | $471K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 21,534 | 20,230 | $438K |
| 99199 | Unlisted special service, procedure or report | 2.8% | 9,080 | 8,087 | $424K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 2,132 | 2,091 | $343K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 11,857 | 11,141 | $315K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 19,213 | 18,357 | $303K |
229 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 34,486 | $268K |
| 99284 | Emergency room visit (serious) | 1.5% | 2,876 | $225K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.4% | 4,205 | $215K |
| Z7502 | 1.3% | 5,663 | $201K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.0% | 2,426 | $158K |
| 99283 | Emergency room visit (moderate) | <1% | 2,557 | $150K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,235 | $136K |
| 0250 | <1% | 13,907 | $129K | |
| 83690 | <1% | 20,004 | $128K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,073 | $121K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,960 | $119K |
| 84484 | <1% | 14,430 | $116K | |
| 87631 | <1% | 3,414 | $114K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,557 | $112K |
| Z9725 | <1% | 2,457 | $105K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,581 | $105K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,460 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,464 | $95K |
| 76830 | Ultrasound, transvaginal | <1% | 1,599 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 695 | $94K |
| 0370 | <1% | 1,008 | $94K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,490 | $91K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,053 | $82K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,352 | $81K |
| 0121 | <1% | 63 | $77K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,274 | $71K |
| 81025 | <1% | 14,140 | $69K | |
| 76801 | <1% | 1,533 | $66K | |
| 81001 | <1% | 9,619 | $64K | |
| 87040 | <1% | 5,291 | $60K | |
| 93971 | <1% | 750 | $52K | |
| J3490 | Unclassified drugs | <1% | 10,587 | $47K |
| 73610 | <1% | 1,642 | $45K | |
| 0761 | <1% | 1,808 | $44K | |
| 81002 | <1% | 14,619 | $43K | |
| 73562 | <1% | 1,629 | $41K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,704 | $39K |
| 85610 | <1% | 8,187 | $38K | |
| 84145 | <1% | 2,797 | $37K | |
| 0710 | <1% | 3,733 | $36K | |
| 73630 | <1% | 1,637 | $36K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,631 | $35K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,356 | $35K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,428 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,107 | $32K |
| 73130 | <1% | 961 | $31K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 748 | $31K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,958 | $30K |
| 0123 | <1% | 14 | $29K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 195 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,565 | $29K |
| 83880 | <1% | 2,442 | $28K | |
| 0360 | <1% | 855 | $26K | |
| 87186 | <1% | 1,823 | $26K | |
| 74018 | <1% | 1,255 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,966 | $23K |
| 73030 | <1% | 867 | $23K | |
| 84702 | <1% | 1,615 | $22K | |
| 83605 | <1% | 3,473 | $22K | |
| 0122 | <1% | 43 | $22K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 302 | $22K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,782 | $21K |
| 85730 | <1% | 3,294 | $20K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 87 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,416 | $19K |
| 93458 | <1% | 72 | $19K | |
| 80179 | <1% | 1,011 | $18K | |
| 80143 | <1% | 1,020 | $18K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,627 | $18K |
| 0270 | <1% | 7,596 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 377 | $17K |
| 85027 | <1% | 2,246 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 808 | $17K |
| 76770 | <1% | 360 | $17K | |
| 73110 | <1% | 803 | $16K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 464 | $16K |
| 85379 | <1% | 2,010 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,614 | $15K |
| 83735 | <1% | 3,239 | $15K | |
| 0171 | Inj, epinephrine (belcher) | <1% | 85 | $15K |
| 87807 | <1% | 404 | $14K | |
| 93970 | <1% | 154 | $14K | |
| 90715 | <1% | 532 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 457 | $13K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 236 | $12K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 282 | $12K |
| 86901 | <1% | 2,543 | $11K | |
| 77080 | <1% | 125 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,892 | $11K |
| 87077 | <1% | 1,328 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,614 | $10K |
| 86710 | <1% | 996 | $10K | |
| 86850 | <1% | 1,312 | $10K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 25 | $10K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,484 | $10K |
| 73140 | <1% | 329 | $9K | |
| 72100 | <1% | 303 | $9K | |
| 86900 | <1% | 2,546 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 554 | $8K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,599 | $8K |
| 86140 | <1% | 1,277 | $8K | |
| 70496 | <1% | 74 | $8K | |
| 70498 | <1% | 60 | $8K | |
| 93798 | <1% | 914 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,846 | $7K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 182 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,854 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,720 | $6K |
| 96376 | <1% | 1,409 | $6K | |
| 80306 | <1% | 413 | $6K | |
| 0636 | <1% | 1,534 | $6K | |
| 85055 | <1% | 503 | $6K | |
| 67311 | <1% | 24 | $5K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,311 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,142 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,316 | $5K |
| 81003 | <1% | 1,702 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,015 | $5K |
| 76870 | <1% | 57 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 999 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,067 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,738 | $4K |
| 84703 | <1% | 925 | $4K | |
| 0300 | <1% | 1,370 | $4K | |
| 0762 | <1% | 135 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,495 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 94 | $3K |
| Z7506 | <1% | 24 | $3K | |
| 86317 | <1% | 521 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 511 | $3K |
| 0306 | <1% | 420 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 28 | $3K |
| 0760 | <1% | 123 | $3K | |
| 73502 | <1% | 111 | $3K | |
| 29125 | <1% | 152 | $3K | |
| 85652 | <1% | 541 | $2K | |
| 0272 | <1% | 790 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 37 | $2K |
| 0410 | <1% | 295 | $2K | |
| V5008 | Hearing screening | <1% | 413 | $2K |
| 99221 | <1% | 95 | $2K | |
| 0324 | <1% | 186 | $2K | |
| 76818 | <1% | 377 | $2K | |
| 0301 | <1% | 595 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 86 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 586 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 69 | $2K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 160 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 49 | $1K |
| 87070 | <1% | 241 | $1K | |
| 87205 | <1% | 298 | $1K | |
| 99152 | <1% | 113 | $1K | |
| 85362 | <1% | 256 | $1K | |
| 87420 | <1% | 199 | $1K | |
| 82550 | <1% | 217 | $1K | |
| 71250 | <1% | 12 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 25 | $995.86 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 16 | $874.65 |
| 72040 | <1% | 40 | $839.15 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 21 | $832.59 |
| 0258 | <1% | 441 | $822.87 | |
| 71101 | <1% | 39 | $805.68 | |
| 72170 | <1% | 52 | $791.45 | |
| 73590 | <1% | 28 | $763.58 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 112 | $650.66 |
| Z7610 | <1% | 65 | $586.17 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 111 | $550.05 |
| 0350 | <1% | 686 | $539.31 | |
| 84439 | <1% | 99 | $517.93 | |
| 71010 | <1% | 51 | $509.56 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 77 | $413.64 |
| A4217 | Sterile water/saline, 500 ml | <1% | 770 | $406.44 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 123 | $385.99 |
| 80061 | Lipid panel | <1% | 105 | $380.58 |
| 80076 | <1% | 13 | $367.67 | |
| A4649 | Surgical supply; miscellaneous | <1% | 358 | $342.64 |
| 0302 | <1% | 393 | $329.44 | |
| 73070 | <1% | 14 | $309.86 | |
| 87486 | <1% | 28 | $285.42 | |
| 87581 | <1% | 28 | $285.42 | |
| 96367 | <1% | 12 | $281.09 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $252.72 |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $231.85 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 27 | $228.95 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 26 | $224.02 |
| 93017 | <1% | 24 | $220.57 | |
| 73090 | <1% | 25 | $214.50 | |
| 82077 | <1% | 14 | $207.80 | |
| 12001 | <1% | 12 | $204.80 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,637 | $197.12 |
| 83615 | <1% | 56 | $173.15 | |
| 0305 | <1% | 622 | $155.52 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 34 | $139.26 |
| 82728 | <1% | 24 | $136.77 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 47 | $124.64 |
| 0940 | <1% | 13 | $110.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 445 | $104.56 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 16 | $99.04 |
| 87088 | <1% | 27 | $95.88 | |
| 87045 | <1% | 14 | $94.83 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 398 | $89.72 |
| 87210 | <1% | 38 | $88.91 | |
| 87081 | <1% | 13 | $79.20 | |
| C1769 | Guide wire | <1% | 96 | $78.46 |
| 84550 | <1% | 13 | $72.32 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 13 | $62.25 |
| 87046 | <1% | 14 | $53.36 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 15 | $51.55 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $35.31 |
| 84132 | <1% | 12 | $19.67 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 14 | $14.44 |
| 0637 | <1% | 68 | $9.58 | |
| 0470 | <1% | 13 | $9.04 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 16 | $7.97 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 16 | $7.14 |
| A9270 | Non-covered item or service | <1% | 127 | $2.11 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 108 | $1.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 39 | $0.77 |
| 0402 | 0% | 47 | $0.00 | |
| 0730 | 0% | 107 | $0.00 | |
| 97116 | 0% | 15 | $0.00 | |
| 0424 | 0% | 24 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
| 0771 | 0% | 16 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 820 | $0.00 |
| 0307 | 0% | 67 | $0.00 | |
| 0720 | 0% | 28 | $0.00 | |
| 0420 | 0% | 25 | $0.00 | |
| 45388 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.